West Pharmaceutical Services Deferred compensation liabilities decreased by 12.9% to $8.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.3%, from $8.60M to $8.80M. Over 5 years (FY 2020 to FY 2025), Deferred compensation liabilities shows a downward trend with a -7.0% CAGR.
other_other_deferred_compensation_arrangements_liability_7bece6| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.50M | $15.70M | $16.10M | $15.40M | $13.20M | $12.60M | $12.70M | $10.60M | $11.30M | $9.30M | $10.40M | $10.10M | $10.60M | $11.40M | $11.20M | $8.60M | $9.60M | $10.10M | $10.10M | $8.80M |
| QoQ Change | — | +1.3% | +2.5% | -4.3% | -14.3% | -4.5% | +0.8% | -16.5% | +6.6% | -17.7% | +11.8% | -2.9% | +5.0% | +7.5% | -1.8% | -23.2% | +11.6% | +5.2% | +0.0% | -12.9% |
| YoY Change | — | — | — | — | -14.8% | -19.7% | -21.1% | -31.2% | -14.4% | -26.2% | -18.1% | -4.7% | -6.2% | +22.6% | +7.7% | -14.9% | -9.4% | -11.4% | -9.8% | +2.3% |